2.75
price down icon0.36%   -0.010
after-market After Hours: 2.80 0.05 +1.82%
loading
Okyo Pharma Limited stock is traded at $2.75, with a volume of 28,744. It is down -0.36% in the last 24 hours and up +11.34% over the past month. OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
See More
Previous Close:
$2.76
Open:
$2.77
24h Volume:
28,744
Relative Volume:
0.16
Market Cap:
$93.05M
Revenue:
-
Net Income/Loss:
$-13.27M
P/E Ratio:
-16.77
EPS:
-0.164
Net Cash Flow:
$-7.70M
1W Performance:
-8.03%
1M Performance:
+11.34%
6M Performance:
+161.90%
1Y Performance:
+103.70%
1-Day Range:
Value
$2.70
$2.7816
1-Week Range:
Value
$2.67
$2.9803
52-Week Range:
Value
$0.8075
$3.11

Okyo Pharma Limited Stock (OKYO) Company Profile

Name
Name
Okyo Pharma Limited
Name
Phone
-
Name
Address
-
Name
Employee
4
Name
Twitter
Name
Next Earnings Date
2024-09-30
Name
Latest SEC Filings
Name
OKYO's Discussions on Twitter

Compare OKYO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
OKYO
Okyo Pharma Limited
2.75 103.81M 0 -13.27M -7.70M -0.164
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Okyo Pharma Limited Stock (OKYO) Latest News

pulisher
Jul 25, 2025

OKYO Pharma Limited Stock Analysis and ForecastMarket-beating returns - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about OKYO Pharma Limited stockMassive stock growth - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Will OKYO Pharma Limited stock benefit from AI tech trendsExplosive market performance - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

What institutions are buying OKYO Pharma Limited stock nowConsistently exceptional gains - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

OKYO Pharma reports promising phase 2 results for urcosimod in neuropathic corneal pain - Pharmafile

Jul 24, 2025
pulisher
Jul 23, 2025

What drives OKYO Pharma Limited stock priceAccelerated wealth expansion - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is OKYO Pharma Limited a good long term investmentPhenomenal trading returns - Autocar Professional

Jul 23, 2025
pulisher
Jul 21, 2025

OKYO Pharma Secures $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain - VisionMonday.com

Jul 21, 2025
pulisher
Jul 19, 2025

OKYO Pharma CEO details positive results from Phase 2 urcosimod trialICYMI - Proactive financial news

Jul 19, 2025
pulisher
Jul 18, 2025

OKYO Pharma Secures $1.9M Non-Dilutive Funding to Advance Urcosimod Development - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

OKYO Pharma announces positive results from phase 2 trial of urcosimod for neuropathic corneal pain - Ophthalmology Times

Jul 18, 2025
pulisher
Jul 17, 2025

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding - GlobeNewswire

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma receives $1.9 million non-dilutive funding for lead drug development - Investing.com Nigeria

Jul 17, 2025
pulisher
Jul 17, 2025

Small cap wrap: Digi Power X, American Resources, OKYO Pharma, Lisata Therapeutics... - Proactive financial news

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Slides Despite Fresh R&D Funding - Baystreet.ca

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma secures $1.9 million in non-dilutive funding for eye drug - Investing.com Canada

Jul 17, 2025
pulisher
Jul 17, 2025

Okyo Pharma Obtains $1.9 Million Non-Dilutive Funding - MarketScreener

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma bolsters ocular pain program with $1.9M non-dilutive financing - Proactive financial news

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma secures $1.9 million in non-dilutive funding for eye drug By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO’s Market Whiplash: 86.16% YTD Rise, -1.66% Plunge in 30 Days - investchronicle.com

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain - MarketScreener

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Secures $1.9M to Fast-Track Revolutionary Eye Pain Drug with No Current FDA Treatment - Stock Titan

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

OKYO Pharma stock maintains Buy rating at H.C. Wainwright on positive trial data - Investing.com Australia

Jul 17, 2025
pulisher
Jul 16, 2025

OKYO Pharma Limited Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain - MarketScreener

Jul 16, 2025
pulisher
Jul 16, 2025

OKYO Pharma Receives Positive Buy Rating from H.C. Wainwright - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation - TipRanks

Jul 16, 2025

Okyo Pharma Limited Stock (OKYO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):